Charles Schwab
ACRS icon

Charles Schwab’s Aclaris Therapeutics ACRS Stock Holding History

Charles Schwab’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.83M Buy
346,058
+85,068
+33% +$379K ﹤0.01% 2817
2026
Q1 		$979K Sell
260,990
-23,614
-8% -$79.7K ﹤0.01% 2913
2025
Q4 		$857K Buy
284,604
+42,648
+18% +$108K ﹤0.01% 2984
2025
Q3 		$460K Sell
241,956
-19,342
-7% -$33.7K ﹤0.01% 3197
2025
Q2 		$371K Buy
261,298
+228,219
+690% +$309K ﹤0.01% 3247
2025
Q1 		$50.6K Hold
33,079
– – ﹤0.01% 3398
2024
Q4 		$82K Buy
+33,079
New +$82.3K ﹤0.01% 3412
2024
Q3 		– Sell
-260,706
Closed -$287K – 3502
2024
Q2 		$287K Sell
260,706
-158,628
-38% -$186K ﹤0.01% 3376
2024
Q1 		$520K Sell
419,334
-16,996
-4% -$20.3K ﹤0.01% 3017
2023
Q4 		$458K Sell
436,330
-26,904
-6% -$82.1K ﹤0.01% 3104
2023
Q3 		$3.17M Buy
463,234
+18,973
+4% +$162K ﹤0.01% 2442
2023
Q2 		$4.61M Buy
444,261
+34,041
+8% +$308K ﹤0.01% 2266
2023
Q1 		$3.32M Sell
410,220
-1,913
-0.5% -$24.3K ﹤0.01% 2374
2022
Q4 		$6.49M Buy
412,133
+9,579
+2% +$154K ﹤0.01% 2073
2022
Q3 		$6.34M Buy
402,554
+248,235
+161% +$3.91M ﹤0.01% 2097
2022
Q2 		$2.15M Buy
154,319
+21,251
+16% +$298K ﹤0.01% 2550
2022
Q1 		$2.29M Buy
133,068
+4,155
+3% +$56.7K ﹤0.01% 2598
2021
Q4 		$1.88M Buy
128,913
+1,997
+2% +$30.3K ﹤0.01% 2722
2021
Q3 		$2.29M Buy
126,916
+19,078
+18% +$306K ﹤0.01% 2668
2021
Q2 		$1.89M Buy
107,838
+92,049
+583% +$2.09M ﹤0.01% 2735
2021
Q1 		$398K Sell
15,789
-4,716
-23% -$92.2K ﹤0.01% 3155
2020
Q4 		$133K Hold
20,505
– – ﹤0.01% 3297
2020
Q3 		$53K Hold
20,505
– – ﹤0.01% 3280
2020
Q2 		$34K Sell
20,505
-64,197
-76% -$86K ﹤0.01% 3275
2020
Q1 		$89K Hold
84,702
– – ﹤0.01% 3117
2019
Q4 		$161K Hold
84,702
– – ﹤0.01% 3061
2019
Q3 		$92K Sell
84,702
-121,887
-59% -$173K ﹤0.01% 3097
2019
Q2 		$453K Buy
206,589
+32,759
+19% +$179K ﹤0.01% 2855
2019
Q1 		$1.04M Sell
173,830
-26,103
-13% -$173K ﹤0.01% 2538
2018
Q4 		$1.48M Buy
199,933
+65,874
+49% +$679K ﹤0.01% 2421
2018
Q3 		$1.95M Buy
134,059
+11,916
+10% +$204K ﹤0.01% 2431
2018
Q2 		$2.44M Sell
122,143
-3,426
-3% -$63.3K ﹤0.01% 2313
2018
Q1 		$2.2M Buy
125,569
+3,802
+3% +$80.6K ﹤0.01% 2299
2017
Q4 		$3M Buy
121,767
+29,260
+32% +$713K ﹤0.01% 2154
2017
Q3 		$2.39M Buy
92,507
+30,742
+50% +$824K ﹤0.01% 2225
2017
Q2 		$1.68M Buy
61,765
+17,804
+40% +$484K ﹤0.01% 2281
2017
Q1 		$1.31M Buy
43,961
+2,736
+7% +$78.9K ﹤0.01% 2340
2016
Q4 		$1.12M Buy
41,225
+16,694
+68% +$426K ﹤0.01% 2392
2016
Q3 		$629K Buy
24,531
+816
+3% +$17.3K ﹤0.01% 2540
2016
Q2 		$439K Buy
23,715
+6,852
+41% +$136K ﹤0.01% 2635
2016
Q1 		$320K Buy
16,863
+306
+2% +$5.85K ﹤0.01% 2744
2015
Q4 		$447K Buy
+16,557
New +$323K ﹤0.01% 2693

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Charles Schwab's ACRS Position: Q2 2026 in Review

Charles Schwab increased its Aclaris Therapeutics (ACRS) stake by 33% in Q2 2026, buying an estimated $379K and bringing the position to 346,058 shares worth $1.83M. The position accounts for ﹤0.01% of the portfolio, ranked #2817.

Charles Schwab first reported a position in ACRS in Q4 2015 and has held it in 42 quarters since. The position peaked at $6.49M in Q4 2022. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Charles Schwab held 346,058 shares of Aclaris Therapeutics worth $1.83M as of Q2 2026.
  • Charles Schwab bought 85,068 Aclaris Therapeutics shares in Q2 2026, an estimated $379K.
  • Aclaris Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2817 holding.
  • Charles Schwab first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 42 quarters since.
  • Charles Schwab's Aclaris Therapeutics position peaked at $6.49M in Q4 2022.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.